Company Filing History:
Years Active: 1997-2008
Title: Suezanne E Parker: Innovator in Cancer Treatment
Introduction
Suezanne E Parker is a prominent inventor based in San Diego, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic methods. With a total of 5 patents, her work focuses on utilizing polynucleotides to enhance cancer therapies.
Latest Patents
Among her latest patents, Suezanne has developed methods for treating cancer using interferon-ω-expressing polynucleotides. This invention provides a pharmaceutical composition that includes a non-infectious, non-integrating polynucleotide construct. This construct encodes an interferon ω and one or more cationic compounds. The methods outlined in her patent involve administering this construct into the tissue of a mammal to treat cancer effectively. Additionally, she has created methodologies for selective transfection of malignant cells with polynucleotides that express therapeutic or prophylactic molecules, particularly in intra-cavity tumor-bearing mammals. Another significant patent focuses on treating cancer using cytokine-expressing polynucleotides, which also involves a similar non-infectious, non-integrating DNA polynucleotide construct.
Career Highlights
Suezanne E Parker is associated with Vical Incorporated, where she continues to advance her research in cancer treatment. Her innovative approaches have positioned her as a key figure in the development of new therapeutic strategies.
Collaborations
Throughout her career, Suezanne has collaborated with notable colleagues, including Peter M Hobart and Michal Margalith. These collaborations have further enriched her research and contributed to the success of her inventions.
Conclusion
Suezanne E Parker's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. Her patents and research continue to pave the way for new treatment methodologies that hold promise for improving patient outcomes.